Bain Capital Life Sciences Investors Portfolio holdings
Bain Capital Life Sciences is an investment firm, started in 2016, that draws on four decades of healthcare investing at Bain Capital. It backs drug, medical device, diagnostics and life science tools companies around the world, through four kinds of deal: Inflection Capital, Growth Capital, Fallen Angels, and bigger private equity partnerships that include forming new companies. Its team has senior experience in the life science industry and in public and private healthcare investing, and can draw on the wider Bain Capital platform.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kailera Therapeutics
KLRA
|
+$496M |
| 2 |
Alkermes
ALKS
|
+$51.9M |
| 3 |
Hemab Therapeutics
COAG
|
+$45.5M |
| 4 |
Cabaletta Bio
CABA
|
+$24.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NewAmsterdam Pharma
NAMS
|
+$115M |
| 2 |
Heartflow Inc
HTFL
|
+$60.1M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$25.2M |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$5.2M |
| 5 |
Annexon
ANNX
|
+$4.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.87% |
| 2 | Miscellaneous | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Kailera Therapeutics
KLRA
$1.67B
| $498M | 29.58% |
+22,583,268
| New | +$496M |
2026 Q2
0 quarters
|
|
|
2
Heartflow Inc
HTFL
$4.36B
| $248M | 14.74% |
8,448,158
-2,000,000
| -19% | -$60.1M |
2025 Q3
3 quarters
|
|
|
3
NewAmsterdam Pharma
NAMS
$2.4B
| $129M | 7.67% |
3,806,566
-3,500,000
| -48% | -$115M |
2022 Q4
14 quarters
|
|
4
Savara
SVRA
$1.03B
| $108M | 6.45% |
17,600,621
| – | – |
2019 Q4
26 quarters
|
|
|
5
Alkermes
ALKS
$7.83B
| $102M | 6.04% |
1,937,938
+1,327,938
| +218% | +$51.9M |
2026 Q1
1 quarter
|
|
6
Solid Biosciences
SLDB
$748M
| $98M | 5.83% |
9,808,819
| – | – |
2018 Q1
33 quarters
|
|
7
Pharvaris
PHVS
$2.34B
| $92.5M | 5.5% |
2,675,509
| – | – |
2021 Q1
21 quarters
|
|
|
8
Olema Pharmaceuticals
OLMA
$665M
| $88.6M | 5.27% |
7,085,249
-387,989
| -5% | -$5.2M |
2024 Q4
6 quarters
|
|
|
9
Hemab Therapeutics
COAG
$1.84B
| $60.6M | 3.6% |
+1,650,000
| New | +$45.5M |
2026 Q2
0 quarters
|
|
|
10
Cabaletta Bio
CABA
$274M
| $53.6M | 3.19% |
17,241,445
+7,564,320
| +78% | +$24.9M |
2023 Q2
12 quarters
|
|
11
X4 Pharmaceuticals
XFOR
$311M
| $37.2M | 2.21% |
7,967,454
| – | – |
2019 Q4
26 quarters
|
|
12
Dianthus Therapeutics
DNTH
$5.1B
| $35.3M | 2.1% |
362,470
| – | – |
2024 Q1
9 quarters
|
|
13
C4 Therapeutics
CCCC
$358M
| $33.5M | 1.99% |
7,171,910
| – | – |
2020 Q4
22 quarters
|
|
14
Kyverna Therapeutics
KYTX
$301M
| $25.7M | 1.53% |
2,885,000
-225,000
| -7% | -$2M |
2024 Q1
9 quarters
|
|
|
15
Annexon
ANNX
$731M
| $25.3M | 1.51% |
4,437,731
-774,943
| -15% | -$4.28M |
2020 Q3
23 quarters
|
|
16
Rapid Micro Biosystems
RPID
$32.1M
| $14.6M | 0.87% |
8,434,560
| – | – |
2021 Q3
19 quarters
|
|
17
Disc Medicine
IRON
$3.64B
| $10.3M | 0.61% |
141,234
| – | – |
2026 Q1
1 quarter
|
|
18
Atea Pharmaceuticals
AVIR
$330M
| $9.7M | 0.57% |
2,075,639
-284,999
| -12% | -$1.42M |
2020 Q4
22 quarters
|
|
19
Xilio Therapeutics
XLO
$56.2M
| $6.36M | 0.38% |
664,021
| – | – |
2021 Q4
18 quarters
|
|
20
Upstream Bio Inc
UPB
$151M
| $4.16M | 0.25% |
600,949
-266,262
| -31% | -$2.23M |
2024 Q4
6 quarters
|
|
|
21
NewAmsterdam Pharma Warrant
NAMSW
| $2.14M | 0.13% |
99,999
| – | – |
2022 Q4
14 quarters
|
|
|
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-635,000
| Closed | -$25.2M | – |
|
Similar funds
Bain Capital Life Sciences Investors's Q2 2026 Portfolio in Review
As of Q2 2026, Bain Capital Life Sciences Investors held 22 positions worth $1.68B, up 52% from $1.11B the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Bain Capital Life Sciences Investors deployed $403M of net new capital in Q2 2026, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Kailera Therapeutics: 22,583,268 shares worth $498M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was NewAmsterdam Pharma, an estimated $115M trimmed.
- Bain Capital Life Sciences Investors's largest Q2 2026 buy was Kailera Therapeutics: 22,583,268 shares worth $498M.
- Bain Capital Life Sciences Investors added most to Alkermes in Q2 2026, an estimated $51.9M increase.
- Bain Capital Life Sciences Investors's biggest Q2 2026 reduction was NewAmsterdam Pharma, cutting an estimated $115M.
- Bain Capital Life Sciences Investors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $25.2M.
- Bain Capital Life Sciences Investors's ten largest holdings make up 88% of its $1.68B portfolio in Q2 2026.
- Bain Capital Life Sciences Investors opened 2 new positions and closed 1 in Q2 2026.
- Bain Capital Life Sciences Investors's portfolio value rose 52% quarter-over-quarter to $1.68B.
Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.